These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7578377)

  • 1. Strategies to prevent nephrotoxicity of anticancer drugs.
    Skinner R
    Curr Opin Oncol; 1995 Jul; 7(4):310-5. PubMed ID: 7578377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
    Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
    J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide, mesna, and nephrotoxicity in children.
    Skinner R; Sharkey IM; Pearson AD; Craft AW
    J Clin Oncol; 1993 Jan; 11(1):173-90. PubMed ID: 8418231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
    Bokemeyer C; Fels LM; Dunn T; Voigt W; Gaedeke J; Schmoll HJ; Stolte H; Lentzen H
    Br J Cancer; 1996 Dec; 74(12):2036-41. PubMed ID: 8980410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic ifosfamide nephrotoxicity in children.
    Skinner R
    Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
    Goren MP; Wright RK; Horowitz ME; Pratt CB
    Cancer Treat Rep; 1987 Feb; 71(2):127-30. PubMed ID: 2879626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    van Hoff J; Grier HE; Douglass EC; Green DM
    Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
    Shibuya M; Hirosawa A; Niitani H
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):950-6. PubMed ID: 2111664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
    Skinner R
    Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
    Zaki EL; Springate JE; Taub M
    Toxicol In Vitro; 2003 Aug; 17(4):397-402. PubMed ID: 12849722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
    Jones DP; Chesney RW
    Curr Opin Pediatr; 1995 Apr; 7(2):208-13. PubMed ID: 7787938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin dose rate as a risk factor for nephrotoxicity in children.
    Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
    Br J Cancer; 1998 May; 77(10):1677-82. PubMed ID: 9635848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for ifosfamide nephrotoxicity in children.
    Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
    Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
    Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
    Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthesis, structure-toxicity relationship of cisplatin derivatives for the mechanism research of cisplatin-induced nephrotoxicity.
    Hu J; Wu TM; Li HZ; Zuo ZP; Zhao YL; Yang L
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3591-3594. PubMed ID: 28579329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity--what do we know and what don't we know?
    Skinner R
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):128-34. PubMed ID: 21285904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.
    Loebstein R; Koren G
    Pediatrics; 1998 Jun; 101(6):E8. PubMed ID: 9606250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.